Ellagic acid activates the Keap1-Nrf2-ARE signaling pathway in improving Parkinson’s disease: A review - 15/11/22

Abstract |
Parkinson's disease (PD) is a familiar neurodegenerative disease, accompanied by motor retardation, static tremor, memory decline and dementia. Heredity, environment, age and oxidative stress have been suggested as key factors in the instigation of PD. The Keap1-Nrf2-ARE signaling is one of the most significant anti- oxidative stress (OS) pathways. The Keap1 is a negative regulator of the Nrf2. The Keap1-Nrf2-ARE pathway can induce cell oxidation resistance and reduce nerve injury to treat neurodegenerative diseases. Ellagic acid (EA) can inhibit the Keap1 to accumulate the Nrf2 in the nucleus, and act on the ARE to produce target proteins, which in turn may alleviate the impact of OS on neuronal cells of PD. This review analyzes the structure and physiological role of EA, along with the structure, composition and functions of the Keap1-Nrf2-ARE signaling pathway. We further expound on the mechanism of ellagic acid in its activation of the Keap1-Nrf2-ARE signaling pathway, as well as the relationship between EA in impairing the TLR4/Myd88/NF-κB and Nrf2 pathways. Ellagic acid has the potentiality of improving PD by activating the Keap1-Nrf2-ARE signaling pathway and scavenging free radicals.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | At present, monoamine oxidase inhibitors, dopamine receptor agonists, and dopamine drugs have side effects in PD treatments. |
• | EA can inhibit Keap1 to accumulate Nrf2 and act on ARE to produce target proteins, which in turn may alleviate the impact of oxidative stress on neuronal cells of PD. |
• | EA enhances the Keap1-Nrf2-ARE pathway and releases downstream proteins, which in turn could protect PD instigated by either inflammation or oxidative stress. |
Keywords : Ellagic acid, Parkinson’s disease, Keap1-Nrf2-ARE signaling pathway, Oxidative stress
Plan
Vol 156
Article 113848- décembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?